Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States (DISCOVERY)
A Phase 1b, Multicenter, Single Dose Gene Transfer Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Subjects in the United States
Sponsor: Sarepta Therapeutics, Inc.
Terminated
Study is being terminated due to a business decision.
Other terminated trials from Sarepta Therapeutics, Inc.
- Duchenne Muscular Dystrophy · Phase PHASE1 · Aug 2025
- Limb Girdle Muscular Dystrophy · Phase PHASE1 · Jun 2025
- Duchenne Muscular Dystrophy · Phase PHASE2 · Feb 2025
- Limb-Girdle Muscular Dystrophy, Type 2E · Phase PHASE1/PHASE2 · Jan 2025
- Duchenne Muscular Dystrophy · Phase PHASE3 · Jul 2023
More terminations from Sarepta Therapeutics, Inc.
Other Limb Girdle Muscular Dystrophy trials with similar outcome
This PHASE1 trial investigates Limb Girdle Muscular Dystrophy and Limb Girdle Muscular Dystrophy Type 2D/R3 and is currently terminated or withdrawn. Sarepta Therapeutics, Inc. leads this study, which shows 5 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Oct 2025 — Present [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
May 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE1
Status: Enrolling By Invitation → Active Not Recruiting
-
Apr 2025 — May 2025 [monthly]
Enrolling By Invitation PHASE1
-
Mar 2025 — Apr 2025 [monthly]
Enrolling By Invitation PHASE1
Status: Not Yet Recruiting → Enrolling By Invitation
-
Jan 2025 — Mar 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sarepta Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .